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Abstract
Background: Many patients’ and consumers’ organizations accept drug industry funding to support their activities. As drug
companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful
means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large
group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites.
Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a
group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name
of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors
are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and
consumer groups’ websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer
groups and 17 drug companies were considered. Thirteen drug companies (76%) named at least one group funded, on their
Italian websites. Of these, four (31%) indicated the activities sponsored and two (15%) the amount of funding. Of the 157
patient and consumer groups, 46 (29%) named at least one pharmaceutical company as providing funds. Three (6%)
reported the amount of funding, 25 (54%) the activities funded, none the proportion of income derived from drug
companies. Among the groups naming pharmaceutical company sponsors, 15 (33%) declared them in a dedicated section,
five (11%) on the home page, the others in the financial report or other sections.
Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups’ websites. The levels of
transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian
pharmaceutical companies’ websites, but information are often not complete.
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Introduction
Patient and consumer groups are increasingly considered an
important point of reference by healthcare agencies, research
institutions, medical societies and the drug industry, thanks to their
role and work for patients. Different aims and interests are at stake
in working with patient groups, such as involving patients in
research projects or clinical studies, consulting patients in advisory
committees or boards, conveying information to patients, lobbying
regulatory agencies and institutions.
As regards drug companies, some of their interests are to boost
knowledge about patients’ needs, improve their image supporting
patient groups as a corporate responsibility activity, and putting
pressure on prescribers and regulatory agencies.
Many patient and consumer groups accept drug industry
funding to support their activities. Some of them see this as the
only way to reach their aims and efficiently respond to patients’
demands [1] - especially considering the lack of public funds -
relying on the capacity of patients groups to defend their
independence from the influence of any sponsor. [1,2] Accepting
funding from the drug industry clearly puts patient organizations
in a condition of potential conflict of interest where their
independence and public trust are at risk, considering the
influence of drug industry funding on sponsored studies or
activities. [3–4] Patient groups can unintentionally promote a
drug or a diagnostic test towards patients- acting as a neutral third
party –they can overlap drug companies’ and patients’ interests in
the policy of their organization; finally, they can be prevented
from making autonomous decisions, especially when patients’
interests differ from those of the drug industry. [1–2,5–6]
Awareness of these risks and the development of policies to
manage them are not common among patient groups and, even if
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funding to the public has not been adequately addressed by patient
groups. [7,8] As drug companies and patient groups move closer,
disclosure and openness become essential for transparency, and
the internet could be a useful means of making sponsorship
information accessible to the public.
Transparency of patient groups in different countries has
been assessed, [7,9–12] but Italian data are rare. [8] The
Laboratory of Medical Research on Consumer Involvement at
Mario Negri Institute own conducted surveys in Italy on
convenience samples of patient groups’ websites (in 2008, 2009).
The results suggested a low level of transparency regarding
funding from the drug industry: only a few websites declared
the funding and published a code of conduct about sponsorship.
Data were presented and discussed with a network of patient
groups during training courses promoted by the Laboratory
(data not published). Data and information must be publicly
available for transparency and the internet offers a good way of
meeting this requirement. The present study assessed the
transparency of a large group of Italian patient and consumer
groups and a group of pharmaceutical sponsor companies,
through defined indicators, focusing on the information reported
on their websites.
Methods
Firstly, the pharmaceutical companies were selected on the basis
of their market sales, then their websites were searched for listings
of patient groups – dealing with specific disease – and consumer
groups – dealing with healthcare rights, quality of healthcare
services, topics of public interest (such as screening programs,
awareness campaigns).
Patient and consumer groups were then selected to obtain the
final sample and, finally, the pharmaceutical companies’ and the
patient and consumer groups’ websites were assessed.
Selection of Pharmaceutical Companies
The drug companies were selected among the top fifteen global
corporations for sales in 2009, [13] adding a group of Italian
companies we considered important for the Italian market (Text
S1).
The Italian and the international websites of each drug
company – if available – were visited on 10 and 31 March
2010, to assess their transparency and select Italian patient and
consumer groups funded. This information was collected by
searching in sections called ‘‘patient associations’’, ‘‘collabora-
tions’’, ‘‘corporate responsibility’’, etc.
Selection of Patient and Consumer Groups
Patient and consumer groups were selected considering the
most recent year of sponsorship available on pharmaceutical
companies’ websites. Groups dealing only with social services and
those strictly related to healthcare professionals or hospitals (i.e.
funded by clinicians, or exclusively dedicated to fund raising for
hospital departments) were excluded.
Two researchers (CC, PM) independently searched for the
websites of selected patient and consumer groups on Google (on
13 and 29 April 2010), using as search terms first the name of
the group, then the name of the disease (for example diabetes,
cancer) or area of interest (for example consumers healthcare).
If the website was not found, the group was excluded from the
survey. Additional information on these groups were sought by
mail.
Evaluation
The transparency of websites of patient and consumer groups
and pharmaceutical companies was assessed, in terms of:
disclosure of sponsorship, amount of funds, activities funded,
accessibility of sponsorship information, code of conduct about
sponsorship, links to other websites. Disclosure information was
compared between the company providing fund and each group
funded.
Patient and consumer groups. Patient and consumer
groups’ websites were examined using a defined form based on
a previous published form. [7] A preliminary version was
developed taking account of the suggestions made by a group of
patients’ representatives during a training course dealing with
conflicts of interest [14]: questions 16 and 21 were added (Text
S2).
The final version of the form was pilot-tested on a random
sample of 47 websites (about 30% of the total websites)
independently evaluated by two reviewers (CC, PM). Discordances
were solved by discussion (July 2010). Concordance on the main
indicator considered, ‘‘Drug industries providing fund to the group
are disclosed in the website’’, was good (82%). Discussion of
discordances led to strict definitions of the criteria to be applied
during the data collection. After the resolution of discordances, the
data of the websites evaluated in the pilot test were included in the
final analysis. The form is divided into general indicators of
transparency, main and secondary indicators related to funding
received from drug companies (Text S2).
Two reviewers (CC, PM) independently assessed the general
indicators and the main indicators of transparency related to
funding received from pharmaceutical companies (websites visited
on May, June, Sept 2010). Discordances were solved by discussion.
The secondary indicators were evaluated by one reviewer
(October 2010).
Transparency and disclosure information were also evaluated
according to the disease of interest and the area of activity of the
patient and consumer groups included. The area of activity was
defined according to the statute of each group – where available –
and the information about activities and projects reported on the
website.
Disclosure practices of patient and consumer groups excluded
from the survey for the lack of a website were also explored. Their
mail addresses or e-mails were searched in the Laboratory’s
database of patient and consumer groups, the list of volunteers’
groups issued by the Italian Revenue Agency, the search engine
Google. They were contacted once, by mail or e-mail, with a short
description of the study and three questions about their disclosure
practices (presence of a code of conduct about sponsorships,
description of the norms…).
Pharmaceutical companies. The transparency of pharma-
ceutical companies’ websites about funding provided to patient
and consumer groups was assessed using a form defined on the
basis of previous studies [7,15]. It is divided into main and
secondary indicators of transparency (Text S3). One reviewer
applied the form to the Italian websites of the 17 drug companies
included. Some indicators were compared on the Italian and
international website of each pharmaceutical company. Disclosure
information available on the websites of pharmaceutical compa-
nies based in Italy was compared to that available on the websites
of pharmaceutical companies based abroad.
Results
In all, 17 pharmaceutical companies were selected. Five have
their headquarter in Italy, 12 abroad (Table 1). At the time of the
Patient and Consumer Groups’ Disclosure of Funding
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funded, for a total of 341 groups. The sponsorships referred to the
years 2008, 2009, 2010, considering the date of update available
(8 websites). Groups listed in these sections included scientific
societies, associations supporting medical research, and groups
dealing with social services. Seven were not identified. Applying
the selection criteria to the 334 groups identified, 177 (53%)
groups in all were excluded from the survey, 101 (30%) for the lack
of a website (Figure 1). One hundred and fifty-seven groups (47%)
were included in the survey (Table 2). These groups are mainly
based in the North of Italy (48%), with a mean age of 19.6 years
(range 2–89). Groups on diabetes are the most common, followed
by groups on cancer, hematology, neurodegenerative diseases,
autoimmune diseases, cardiovascular diseases, AIDS HIV, trans-
plants, behavioral disorders, respiratory diseases, other diseases
(such as growth hormone deficiency, psoriasis…) and consumer
groups.
Transparency of Patient and Consumer Groups’ Websites
More than a quarter of the websites (n. 46, 29%) named at least
one pharmaceutical company as providing funding (Table 3). Of
these, three (6%) reported the amount of funding received, 25
(54%) named activities funded, none reported the proportion of
income derived from the drug industry. Fifteen groups disclosed
the name of drug companies in a dedicated section (33% of those
disclosing), 5 (11%) on the home page, the others only in the
financial report (n. 5, 11%) or in other sections not specifically
dedicated to sponsors (n. 21, 45%). As a result, the availability of
information about sponsorships varied widely on the websites. The
date of update of sponsorships was reported by 29 groups (63% of
those disclosing the drug companies sponsors), nine (less than 20%)
stated that the funding was unrestricted.
Drug industry logos were used in 26 websites (17% of all
groups), banner advertisements of products (drugs, medical devices
or booklets made by drug companies) were reported by 17
websites (about 11%), 42 (27%) had links to drug industry websites
or strictly related to drug industries.
A financial report was published by 30 groups (19% of all
groups). Of these, sixteen (53%) were updated to 2009, the others
were not updated. The number of members (individuals or
corporate members, respectively of single groups or federations)
were not reported by 106 groups (67%); 68 websites (43%)
displayed banner advertising (any commercial advertising, not
only of drug companies’ products) on the home page; most of them
(80%) clearly separated the editorial content from advertising.
Editorial policy – a clear statement describing what procedure is
used for selecting content- was hardly ever explained (only 2%).
Table 3 summarizes the findings.
Transparency by disease and area of activity. Patient
and consumer groups were classified by disease and area of activity
to assess the transparency of websites. Groups on diabetes (n.49,
31%) are the most common type of patient group represented in
the sample, followed by groups on cancer (n. 24, 15%),
hematology (n.21, 13%) and neurodegenerative diseases (n.12,
8%).
Table 3 lists some indicators of transparency by disease of
interest. Differences should be considered in relation to the
number of groups per disease, and the selection criteria applied.
Taking these limits into account, for some disease there is a large
number of websites publishing banner advertisements, links to
drug company websites, or sites related to drug companies, and, at
the same time, only a few websites publishing financial reports,
disclosing drug industry sponsorships, or publishing codes of
conduct about sponsors. For example, 31% of groups on diabetes
disclosed pharmaceutical companies providing funds, 55% pub-
lished banner advertising, 55% linked to drug companies’ websites
or websites sponsored by drug companies, 10% published the
financial report, 4% a code of conduct dealing with sponsorship.
Twenty-nine per cent of groups on cancer disclosed pharmaceu-
tical companies providing funds, 12% linked to drug companies’
websites or websites sponsored by drug companies, 25% published
the financial report and 8% a code of conduct. Fourteen per cent
of hematology groups disclosed pharmaceutical companies
providing funds, 5% linked to drug companies’ websites or
websites sponsored by drug companies, 33% published the
financial report and no one published a code of conduct.
Groups were also divided into two groups according to their
area of activity: nationwide and regional or province and local
areas. National and regional groups were more likely to disclose
sponsorships from the pharmaceutical industry and to publish
codes of conduct than the provincial and local ones (significant
results; data not shown).
Transparency of Drug Companies’ Websites
According to the patient groups’ websites disclosing the drug
companies providing sponsorships, each of the selected drug
companies supported at least one of the patient or consumer
groups included in the survey (one through its foundation).
Thirteen of the 17 drug companies (76%) named at least one
patient or consumer group funded, on their Italian websites.
Four indicated the projects or activities sponsored and two the
amount of funding (Table 4). Reference to the activities
sponsored varied for drug companies, from detailed description
to generic mention of the type of activity (e.g. education,
information, advocacy).
Among the 13 drug industry websites disclosing sponsorships,
11 (85%) declared them in a dedicated section (as ‘‘patient
associations’’, ‘‘collaborations’’, ‘‘grants’’, ‘‘corporate responsibil-
ity’’, etc.), the others reported them in different areas covering for
example specific projects. Five websites (38% of those declaring
sponsorships) had links to sponsored patient and consumer groups
websites. Fifteen drug companies (88%) published codes of
conduct dealing with sponsorship, on their websites (Table 4).
Disclosure information available on the Italian
pharmaceutical companies websites and others. Thirteen
drug companies had an international website as well as the Italian
one. Nine gave different information on the Italian website and the
international one for at least one of the indicators of transparency
considered. Four declared on the international website that they
supported Italian patient or consumer group different in number
Table 1. Main details of the 17 pharmaceutical companies.
Headquarter based in n. (%)
Italy 5 (29)
Other European countries 7 (41)
United States 5 (29)
Annual revenue 2009, EU billion mean; range
All 19.5; 0.5–43.1
Italian headquarter (n.5) 1.2; 0.5–2.8
Description of drug companies included in the survey: headquarter, annual
revenue (2009) for all the drug companies and the Italian ones (mean and
range).
doi:10.1371/journal.pone.0034974.t001
Patient and Consumer Groups’ Disclosure of Funding
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the sponsored projects only in the international website, three the
amount of funding.
Comparing the five pharmaceutical companies based in Italy
and the 12 based abroad, respectively 3 (60%) and 10 (83) named
at least one patient and consumer group provided with funding.
None of the Italian pharmaceutical companies reported the
projects funded, or the amount of funding.
Information about Funding Reported on Pharmaceutical
Companies’ Websites and Patient and Consumer groups’
Websites
Correspondence was low between sponsorships disclosed by
drug companies and by patient consumer groups. All the patient
and consumer groups received funding from the drug industry -
according to the information available on pharmaceutical
companies websites - however, only 46 (29%) stated they received
funding, for a total of 162 sponsorships from drug companies (the
range of drug companies sponsors for single group was 1–11).
Thirty patient and consumer groups (65%) stated at least one drug
company corresponding to the disclosure made by the drug
company itself. The other groups (35%) declare other drug
companies as sponsors. A fourth of the 162 sponsorships disclosed
corresponded to the disclosure made by the 13 drug companies
considered (data not shown). On the other side, each drug
company supported at least one patient or consumer group, but
only 13 mentioned it.
Patient and Consumer Groups with no Website
Eighty-five groups (84% of 101)– whose addresses (mail or e-
mail) were found – were contacted (January 2011). Three (4%)
responded to our questions about their disclosure practices: two
had no code of conduct about sponsors, one had a code but did
not specify the norms or give us examples of its application.
Discussion
Transparency of Patient and Consumer Groups
The patient and consumer groups with websites selected for this
survey cover a wide range for disease of interest, number of
members and area of activity. The collected data refer to Italy,
even so the findings are relevant also to other countries.
The disclosure of sponsorships on patient and consumer groups’
websites is scant and poorly accessible. Only 13% of all the groups
disclosed funding from pharmaceutical companies in a easily
accessible area, the others solely in the financial report or in
sections dealing with single activities, often on brochures or posters
of sponsored events.
Few patient and consumer groups declared the type of activity
funded (16% on all the groups). Educational activities, including
spread of information and meetings, were the most funded. The
date of update of sponsorships was lacking on a third of the groups’
websites declaring sponsorships and the level of transparency was
also low for financial reports.
It was impossible to quantify the funding received by each
patient and consumer group, as the information was only
Figure 1. Flow chart. The drug companies were selected among the top fifteen global corporations for sales in 2009, adding a group of Italian
companies important on the Italian market. Their websites were searched for listings of patient and consumer groups funded. Groups dealing only
with social services and strictly related to healthcare professionals or hospitals were excluded. The websites of selected patient and consumer groups
were searched on Google. If the website was not found, the group was excluded from the survey. ‘ Additional information of groups with no
website were sought by mail. * 76 groups not responding to the inclusion criteria: 33 dealing with social services or supporting sports or social
activities; 38 scientific organizations, or dedicated to fundraising for medical research, or hospital department, or mainly composed of healthcare
operators; 5 groups based in countries other than Italy (listed among the Italian organizations).
doi:10.1371/journal.pone.0034974.g001
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an idea, the two drug companies reporting this data on their
websites funded a minimum of 1,500 and a maximum of
90,000 Euros per group (in 2009). It was also impossible to
quantify the proportion of funding received by the groups on
the total amount of funds, which is an important indicator of
their independence from the sponsor. The only drug company
reporting this on its website said it funded from less than 5% to
almost 30% of the total budget of a single group (in 2009).
The scant attention to disclosure of conflicts of interest is
confirmed by the lack of codes of conduct related to sponsors for
most of the patient and consumer groups. Previous surveys on
disclosure of funding on patient groups’ websites found that most
of them did not declare sponsorships from drug industry, with
some differences between countries. [7,12–15] According to a
survey of 69 websites of patient and consumer groups based in the
United States, United Kingdom, Australia, South Africa and other
international groups (none in Italy), 45% declared they received
funding from the drug industry, none reported the proportion of
funding, one third showed drug companies logos and/or links to
their websites. [7] A survey on patient groups in the United States
and funded by Eli Lilly gave even more alarming results: only a
fourth of groups acknowledged the sponsor on their websites. [12].
As the patient and consumer groups based abroad, also the
Italian ones do not usually declare the amounts received.
According to the results of this survey, patient and consumer
groups with a broad area of activity (at national or regional level)
are more likely to declare to receive funding from the drug
industry.
Transparency of Drug Company Websites
Most of the websites of Italian drug manufactures declared they
sponsored at least one patient and consumer group. Availability of
information was very variable and only few companies fully
disclosed sponsorships: only four (Pfizer, Novartis, GSK, MSD)
indicated the patient and consumer groups’ activities funded, two
the amount of funding (Pfizer, GSK). Indirect support was not
reported - for example financial support for participation in
training courses. Sponsorship information available on Italian
websites was generally less complete than on the international
websites.
Considering both Italian and international websites, about half
the drug companies reported funded projects. Less than a third
reported the amount of funding. All except two published codes of
conduct dealing with patient and consumer groups.
The policy on disclosure of sponsorships varies according to the
legislation of the country where a company is based and the
national or international codes of conduct followed by the drug
industry. Different codes of conduct deal with this issue. The code
of the European Federation of Pharmaceutical Industries and
Associations (EFPIA) [16] adopted by the EFPIA board on 5
October 2007 states that each drug company must make public a
list of patient groups to which it provides financial support and/or
significant indirect/non-financial support. This should include a
short description of the nature of the support. This information
may be provided on a national or European level and should be
updated at least once a year. The Association of the British
Pharmaceutical Industry [17] complies with the EFPIA code,
specifying that companies must make public a list of all groups to
which they provide support by means of information on their
websites or in their annual reports. Farmindustria - an association
of all the Italian drug companies included in the survey – also
complies with the EFPIA code and specify that companies must
make public on their websites a list of all groups to which they
provide support. [18] The date of the code was September 2009.
Finally, the Association of Voluntary Self-Regulation for the
Pharmaceutical Industry (FSA, German) demands public disclo-
sure of the amount of funding given to patient and consumer
groups, for the year and the group supported (date of the code:
June 2008). [19] Some requirements of the reference codes of
conduct were not met by some of the drug companies in this study,
Table 2. Main details of 157 patients and consumers groups.
Base n. (%)
Northern Italy 76 (48)
Central Italy 55 (35)
Southern Italy 26 (17)
Area of activity
National 49 (31)
Regional 29 (18)
Provincial 63 (40)
Local 16 (10)
Years from foundation mean; range
Data available for 139 (88%) organizations’ websites 19.6; 2–89
N. of members mean; range
Data available for 51 (32%) organizations’ websites
Organizations/groups* 23; 17–85
Sections** 47; 4–300
Individual members** 2,204; 17–13,930
Disease or area of interest
diabetes 49 (31)
cancer 24 (15)
hematology 21 (13)
neurodegenerative diseases 12 (8)
autoimmune diseases 10 (6)
AIDS/HIV 6 (4)
cardiovascular diseases 5 (3)
transplants 5 (3)
behavioral disorders 4 (2)
respiratory diseases 2 (1)
other diseases
‘ 12 (8)
consumer groups 7 (4)
*federations or coalitions (comprising many organizations).
**for single organizations the number of sections (local units) is reported if
available on the website, otherwise the number of volunteers/individuals is
given.
‘organizations not included in other categories: e.g. growth hormone
deficiency, psoriasis, inflammatory bowel disease, osteoporosis, prevention of
blindness.
Description of patient and consumer groups included in the survey:
headquarter, main area of activities (going from the larger areas – i.e. regions –
to the smaller ones – i.e. single cities or municipality), age (mean and range),
number of members (mean and range) classified as: number of groups (for
coalitions or federations), number of sections or local units (for single
organizations), number of individuals (for single organizations); disease of
interest.
doi:10.1371/journal.pone.0034974.t002
Patient and Consumer Groups’ Disclosure of Funding
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drug companies selected, 4 did not disclose any patient groups
funded, even if each of them supported at least one of the patient
or consumer groups included in the survey. Among the 13
international websites of the drug companies selected, only five
reported the sponsored projects, three the amount of funding.
Strict control on the implementation of the codes of conduct
by EFPIA, Farmindustria, FSA could be useful to improve the
drug companies’ disclosure practices. Finally, governmental
agencies and other interested stakeholders should require a
public, understandable and detailed disclosure of funding to
patient and consumer groups from drug companies and monitor
the transparency of information reported on the drug companies
websites.
This survey has some limits. First, some of the discrepancies
between drug companies’ and patients’ websites could be
explained because they may not relate to the same period of
time, also because websites, in particular sections reporting
sponsorships, were not all updated regularly.
Second, among the patient and consumer groups funded by the
drug companies included in the sample, many had not a website.
To confirm the lack of a website and to explore their disclosure
practices, these groups were contacted once by mail or e-mail with
few questions on sponsorships. Only three groups responded, so it
was not possible to collect data on the disclosure practices of these
groups.
Conclusions
Transparency in the relationships between patient and con-
sumer groups and drug companies is essential for the credibility of
both. It is also necessary for patient, consumers and other
stakeholders to critically appraise the messages, demand or
proposals from patient and consumer groups and assess which
best represents the patients’ point of view.
Complete and accessible information about sponsorships on
drug industries’ websites is needed (including the amount of
funding for each patient and consumer group, direct and indirect
support, the activities supported) and the codes of conduct should
be stricter than the current ones, in line with the disclosure
requirements for support to health professionals. [20].
This regards holds for patient and consumer groups. As they lie
at the center of many interests, they should boost their autonomy
and their independence from sponsors. Some refuse drug industry
funding in order to maintain their autonomy, others accept it
under certain conditions. Considering that undue pressure and
influence can come even from other sponsors, such as public
agencies, medical societies or research institutes, relationships with
sponsors and common policies to maintain independence should
be discussed by the patient groups themselves. Even if some Italian
patient groups have policies and codes of conduct for these issues,
the levels of transparency, disclosure and ability to manage
relationships with sponsors need to be improved.
Many patient and consumer groups do not have a website.
Considering the increasing use of internet by patients and
consumers searching for healthcare information, [21] they should
consider to create their own website, in order to strength their role
and increase their transparency towards the public.
Patient and consumer groups’ websites should be clearer and
more accessible, they should dedicate a section for sponsorships,
declaring the amount of funding received and the activities
funded.
Supporting Information
Text S1 Drug companies included in the survey.
(DOC)
Table 4. Disclosure information on 17 pharmaceutical companies’ websites providing funds to patient and consumer
organizations.
Principal indicators n( % )
Disclosure of the name of at least one patient or consumer organization funded
‘ 13 (76)
If yes, the amount of funding is reported 2( 1 5 )
If yes, activities funded are reported* 4( 3 1 )
Secondary indicators
Funded patient and consumer organizations are disclosed:**
in a dedicated section 11 (85)
in other sections 2( 1 5 )
Date of update of sponsorships is available** 8( 6 1 )
Links to websites of funded patient and consumer organizations** 5( 3 8 )
Code of conduct dealing with patients and consumers organizations 15 (88)
An international website 13 (76)
If yes, information about sponsorship is different from that on the Italian website 9 (77)
‘March 2010.
*Reference to the activities funded varied among drug companies, from detailed description to generic mention of the type of activity.
**Percentages refer to the drug companies reporting patient and consumer organizations funded.
The transparency of drug companies’ websites was assessed in terms of: disclosure of patient and consumer groups funded, amount of funds, activities funded;
accessibility of sponsorship information; date of update of sponsorship; links to websites of funded patient and consumer groups; availability of a code of conduct on
the relationships with patient and consumer groups; different sponsorships information between the international and the Italian website of the drug company.
According to the patient groups’ websites, each of the selected drug companies supported at least one of the patient or consumer groups included in the survey (one
through its foundation).
doi:10.1371/journal.pone.0034974.t004
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Text S3 Form assessing the transparency of drug
companies’ websites about funding provided to patient
and consumer groups.
(DOC)
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